SMMT 23.76 Summit Therapeutics Inc.
| Range: | 1.64-33.89 | Vol Avg: | 4985926 | Last Div: | 0 | Changes: | 1.34 |
| Beta: | -0.97 | Cap: | 14.45B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 05 2015 | Empoloyees: | 105 | ||
| CUSIP: | 86627T108 | CIK: | 0001599298 | ISIN: | US86627T1088 | Country: | US |
| CEO: | Mr. Robert W. Duggan | Website: | https://www.summittxinc.com | ||||
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Stock Details
SMMT 23
Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
Yigal Nochomovitz·Fri Sep 27 2024
Summit Redstone Partners
SMMT 40
Summit Therapeutics plc (SMMT) PT Raised to $40 at Stifel
Brad Canino·Wed Sep 25 2024
Stifel Nicolaus
SMMT 45
Summit Therapeutics price target raised to $45 from $30 at H.C. Wainwright
Mitchell Kapoor·Mon Sep 16 2024
H.C. Wainwright
SMMT 14
Summit Therapeutics plc (SMMT) PT Raised to $14 at Stifel
Brad Canino·Mon Jun 03 2024
Stifel Nicolaus
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow